Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Atea Pharmaceuticals, Inc. (AVIR) had Consolidated Net Income/Loss of $-42.05M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-42.05M |
|
-- |
|
-- |
|
$45.57M |
|
$-45.57M |
|
$3.71M |
|
$-41.85M |
|
$-41.85M |
|
$-42.05M |
|
$-42.05M |
|
|
Consolidated Net Income/Loss |
$-42.05M |
$-42.05M |
|
$-45.57M |
|
$-46.54M |
|
79.05M |
|
79.05M |
|
$-0.53 |
|
$-0.53 |
|
| Balance Sheet Financials | |
$336.14M |
|
$0.56M |
|
$6.83M |
|
$342.96M |
|
$20.18M |
|
-- |
|
$7.01M |
|
$27.18M |
|
$315.78M |
|
$315.78M |
|
$315.78M |
|
78.13M |
|
| Cash Flow Statement Financials | |
$-103.81M |
|
$142.20M |
|
$-25.75M |
|
$64.70M |
|
$77.34M |
|
$12.65M |
|
$16.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-103.81M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.32% |
|
-13.32% |
|
-12.26% |
|
-13.32% |
|
$4.04 |
|
$-1.31 |
|
$-1.31 |
|